Skip to content

Repetitive Transcranial Magnetic Stimulation in the treatment of Catatonia

For patients with Catatonia, can repetitive Transcranial Magnetic Stimulation (rTMS), affect the symptoms and presentation of the illness.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612001174875
Enrollment
10
Registered
2012-11-06
Start date
2013-02-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Catatonia is a neuropsychiatric syndrome that can occur due to medical or psychiatric disorder. It is a behavioral syndrome that can be associated with schizophrenia, shizoaffective disorder, or atypical psychosis. ECT was found to be effective for both catatonic stupor and excitement, where benzodiazepine or neuroleptics may not prove successful, and has proven to increase intracortical inhibition (ICI) which is reduced in patients with schizophrenia. Since TMS has been shown to alter cortical excitability, this provides a rationale for moving from ECT to TMS based treatment. Essentially arguing by analogy with ECT, and its effect in depression, three case reports appear to show an ECT-like effect of rTMS in catatonic schizophrenia. All studies used facilitatory fast rTMS (10Hz and 20Hz) although on opposite sides of the prefrontal cortex. In this study we will replicate the best practice application of rTMS in the treatment of catatonia. Since this paradigm is similar to an existing treatment for depression at our unit, no additional preparation is required. As suitable participants are expected to be uncommon, a case series approach will allow us to recruit opportunistically, over an extended period, as clinically warranted. Findings will be reported as a series of case studies, or accumulated as a case series report, depending on the number of cases. This is a fairly novel application of rTMS, but builds on our unit’s experience with rTMS, and Dr Lee’s previous experience in catatonia research, to contribute to this emerging field. The objective is to answer two questions. Whether rTMS will affect catatonia, and what are the clinical circumstances that indicate rTMS treatment. A series of case findings will give an indication of an answer, and inform local treatment consideration.

Interventions

Repetitive Transcranial Magnetic Stimulation (rTMS). This clinical trial will be conducted with a single arm of rTMS, with the standard arm parameters used derived from our estimate of best practice. A MagStim Rapid magnetic stimulator (Magstim, Whitland, UK), connected with a figure-of-eight coil with a diameter of 70mm, will be used to deliver stimuli with the coil handle pointing posteriorly and 45degrees below the coronal plane. Prior to the commencement of the treatment course, resting mo

Repetitive Transcranial Magnetic Stimulation (rTMS). This clinical trial will be conducted with a single arm of rTMS, with the standard arm parameters used derived from our estimate of best practice. A MagStim Rapid magnetic stimulator (Magstim, Whitland, UK), connected with a figure-of-eight coil with a diameter of 70mm, will be used to deliver stimuli with the coil handle pointing posteriorly and 45degrees below the coronal plane. Prior to the commencement of the treatment course, resting motor threshold is measured with single-pulse TMS applied to the motor cortex. The resting motor threshold was measured as the minimal stimulator intensity producing a visible peripheral motor evoked potential response by inspection. A total of 2000 pulses (40 trains) will be delivered in a session (20 minutes). 10Hz for 5 seconds, with 25 second break between trains. Intensity is set at 100% of magnetic threshold. Application over the left dorsolateral prefrontal cortex (LDPFC) Daily sessions will continue up to a maximum of 10 (2 weeks, 20000 pulses).

Sponsors

North Metropolitan Area Health Service
Lead SponsorGovernment body

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

DSM-IV diagnosis of catatonia. Subsequent catatonia scale scores will act as a validation check (any discrepancies to be reviewed by CI), but initial inclusion will be purely by clinical diagnosis.

Exclusion criteria

Presence of cardiac pacemakers, medication pumps, cochlear implants or metal objects in the head or eyes that could be dangerous if heated or moved by the magnetic pulses. Significant medical illness, substantial risk of suicide, current substance dependence, a history of seizures, epilepsy, stroke or major head trauma, or a history of alcohol dependence.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026